Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 7/2009

01-07-2009 | Urologic Oncology

Caspase 9 and Caspase 8 Gene Polymorphisms and Susceptibility to Bladder Cancer in North Indian Population

Authors: Ruchika Gangwar, MSc, Anil Mandhani, MCh, Rama Devi Mittal, PhD

Published in: Annals of Surgical Oncology | Issue 7/2009

Login to get access

Abstract

Background

Dysregulation of apoptosis plays a crucial role in carcinogenesis. Our aim was to investigate the association of Caspase 9 and Caspase 8 gene polymorphism with bladder cancer (BC) susceptibility.

Methods

We undertook a case–control study of 212 (BC) cases and 250 controls to investigate the association between Caspase 9-1263A > G, Caspase 9-293del, and Caspase 8-6 N ins/del polymorphism and BC susceptibility by polymerase chain reaction (PCR) restriction fragment length polymorphism (RFLP) method, and further to study the influence on recurrence in patients after Bacillus Calmette–Guerin (BCG) immunotherapy.

Results

Overall, no statistically significant association was observed in Caspase 9-293del and Caspase 8. Nevertheless, Caspase 9-1263GG genotype was at reduced risk of BC [p = 0.010; odds ratio (OR) = 0.487]. Caspase 9-1263AG genotype was also observed to be significantly associated with reduced risk with high-risk non-muscle-invasive bladder cancer (NMIBC) (TaG2-3, T1G1-3) and invasive tumors (T2 +) of BC (P = 0.042, OR = 0.39 and P = 0.013, OR = 0.028 respectively). Caspase 9-293del, heterozygous (–/+) genotype, too, demonstrated protective effect in high-risk NMIBC (P = 0.017; OR = 0.205). Haplotype analysis revealed variant genotypes Caspase 9AG + GG/Caspase 8 DI + II to be at reduced risk of BC (= 0P.014, OR = 0.47). The GG genotype of Caspase 9-1263 was associated with reduced risk for recurrence in BCG-treated patients [hazard ratio (HR) = 0.217, P = 0.005], thus showing increased recurrence-free survival (log-rank P = 0.024).

Conclusion

Polymorphism in Caspase 9-1263 was observed to play a protective role in susceptibility to BC risk. Caspase 9 gene variants were also associated with reduced risk of NMBIC stages. The variant G allele at Caspase 9-1263 may be responsible for increased recurrence-free survival in BCG-treated patients.
Literature
1.
Ibrahim AS, Khalid HM. Urinary bladder cancer, Mecc Monograph, Chapter 11, 2006:97–109, National Cancer Institute, Bethesda, MD.
2.
Takagi Y, Takashi M, Koshikawa T, Ohshima S. Immunohistochemical demonstration of cyclin D1 in bladder cancers as an inverse indicator of invasiveness but not an independent prognostic factor. Int J Urol. 2000;7:366–72.PubMedCrossRef
3.
Wagner U, Suess K, Luginbuhl T, Schmid U, Ackermann D, Zellwegener T. Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer. J Pathol. 1999;188:44–50.PubMedCrossRef
4.
Bevers RFM, Kurth KH, Schamhart DHJ. Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br J Cancer. 2004;91:607–12.PubMed
5.
Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988;335:440–2.PubMedCrossRef
6.
Lockshin RA, Zakeri Z. Programmed cell death and apoptosis: origins of the theory. Nat Rev Mol Cell Biol. 2001;2:542–50.CrossRef
7.
Hockenbery D, Nuñez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 348,334-336.
8.
Fennell DA. Caspase regulation in non-small cell lung cancer and its potential for therapeutic exploitation. Clin Cancer Res. 2005;11:2097-2105.PubMedCrossRef
9.
10.
11.
Park JY, Park JM, Jang JS, Choi JE, Kim KM, Cha SI, et al. Caspase 9 promoter polymorphisms and risk of primary lung cancer. Hum Mol Genet. 2006;15:1963–71.PubMedCrossRef
12.
Sun T, Gao Y, Tan W, Ma S, Shi Y, Yao J, et al. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet. 2007;39:605–13.PubMedCrossRef
13.
Colombel M, Soloway M, Akaza H. Epidemiology, staging, grading and risk stratification of bladder cancer. Eur Urol Suppl. 2008;7:618–26.CrossRef
14.
Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acids Res. 1988;16:1215.PubMedCrossRef
15.
Larsson P, Wijkström H, Thorstenson A, Adolfsson J, Norming U, Wiklund P, et al. A population-based study of 538 patients with newly detected urinary bladder neoplasms followed during 5 years. Scand J Urol Nephrol. 2003;37:195–201.PubMedCrossRef
16.
Thatte U, Dahanukar S. Apoptosis: clinical relevance and pharmacological manipulation. Drugs. 1997;54:511–32.PubMedCrossRef
17.
Kelly JD, Williamson KE, Irvine AE, Hamilton PW, Weir HP, Anderson NH, et al. Apoptosis and its clinical significance for bladder cancer therapy. BJU Int. 1999;83:1–10.PubMedCrossRef
18.
Twiddy D, Cain K. Caspase-9 cleavage, do you need it? J Biochem. 2007:405.
19.
Haiman CA, Garcia RR, Kolonel LN, Henderson BE, Wu AH, LeMarchand L. A promoter polymorphism in the CASP8 gene is not associated with cancer risk. Nat Genet. 2008;40:259–60.PubMedCrossRef
20.
Pittman AM, Broderick P, Sullivan K, Fielding S, Webb E, Penegar S, et al. CASP8 variants D302H and-652 6 N ins/del do not influence the risk of colorectal cancer in the United Kingdom population. Br J Cancer. 2008;98:1434–6.PubMedCrossRef
21.
Wang M, Zhang Z, Tian Y, Shao J, Zhang Z. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter associated with risk and progression of bladder cancer. Clin Cancer Res. 2009;15:2567–72.PubMedCrossRef
22.
Frank B, Rigas SH, Bermejo JL, Wiestler M, Wagner K, Hemminki K, et al. The CASP8 -652 6 N del promoter polymorphism and breast cancer risk: a multicenter study. Breast Cancer Res Treat. 2008;111:139–44.PubMedCrossRef
Metadata
Title
Caspase 9 and Caspase 8 Gene Polymorphisms and Susceptibility to Bladder Cancer in North Indian Population
Authors
Ruchika Gangwar, MSc
Anil Mandhani, MCh
Rama Devi Mittal, PhD
Publication date
01-07-2009
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 7/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0488-3

Other articles of this Issue 7/2009

Annals of Surgical Oncology 7/2009 Go to the issue

Hepatobiliary and Pancreatic Tumors

Is Laparoscopic Liver Resection Safe and Comparable to Open Liver Resection for Hepatocellular Carcinoma?

Breast Oncology

Recall of and Reactions to a Surgeon Referral Letter for BRCA Genetic Counseling Among High-Risk Breast Cancer Patients

Gastrointestinal Oncology

Genetic Susceptibility to Gastrointestinal Cancer: Minireview of the Genomewide Studies

Consensus Report: Resectable and Borderline Resectable Pancreas Cancer

Surgical Treatment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement by Evans et al.

CONSENSUS REPORT: RESECTABLE AND BORDERLINE RESECTABLE PANCREAS CANCER

Surgical Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Statement

Translational Research and Biomarkers

Dickkopf-1 Expression as a Marker for Predicting Clinical Outcome in Esophageal Squamous Cell Carcinoma